Amycretin vs Amylin
GLP-1 and amylin agonism combined in a single molecule, not a two-drug combination. Co-secreted with insulin; the satiety and gastric-emptying partner. Side by side: type, evidence tier, receptor, molecular weight, and half-life — the same fields as each monograph, rearranged so the engineering difference is visible.
Amycretin | Amylin IAPP | |
|---|---|---|
| Also known as | — | — |
| Type | Analog | Endogenous |
| Evidence | Investigational | Established |
| Family | Incretins & metabolic | Incretins & metabolic |
| Class | Unimolecular GLP-1 + amylin receptor agonist (peptide) | Islet amyloid polypeptide (37 aa) |
| Receptor | GLP-1 receptor + amylin receptors | Amylin receptors (calcitonin receptor + RAMP complexes) |
| Molecular weight | ≈7,900 Da | ~3,903.3 Da |
| Half-life | ~days (weekly SC dosing) | |
| Based on | Amylin | Native hormone |
Half-life bars are on a logarithmic scale across the molecules shown. Reference values for the native or representative form — educational only, not medical or dosing advice.
Common questions
- What is the difference between Amycretin and Amylin?
- Amycretin is an engineered analog based on Amylin; Amylin is an endogenous hormone. Amycretin signals at GLP-1 receptor + amylin receptors; Amylin signals at Amylin receptors (calcitonin receptor + RAMP complexes).
- How do the half-lives of Amycretin and IAPP compare?
- The reported circulating half-life of Amycretin is ~days (weekly SC dosing); Amylin is ~13 min (native). These are reference values for the native or representative form — educational only, not dosing advice.
Prefer the other order? Amylin vs Amycretin. Or open the interactive comparison tool to add more molecules.